Screener
Janux Therapeutics JANX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Assets | June 30,2026 / (unaudited) | December 31,2025 |
|---|---|---|
| Accounts receivable, net | 149 | — |
| Short-term investments | 943,145 | 914,233 |
| Prepaid expenses and other current assets | 12,275 | 9,320 |
| Total current assets | 983,337 | 975,887 |
| Restricted cash | 816 | 816 |
| Property and equipment, net | 3,260 | 3,852 |
| Operating lease right-of-use assets | 17,327 | 18,402 |
| Other long-term assets | 2,913 | 2,608 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's total current assets?
- Janux Therapeutics (JANX) reported total current assets of $983.34M in Q2 2026.
- How has Janux Therapeutics's total current assets changed year-over-year?
- Janux Therapeutics's total current assets decreased by 2.2% year-over-year, from $1.01B to $983.34M.
- What is the long-term trend for Janux Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Janux Therapeutics's total current assets has grown at a 127.4% compound annual growth rate (CAGR), from $16.06M to $975.89M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Janux Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude